New data for genentech's vabysmo reinforce its efficacy, safety and durability in wet age-related macular degeneration (amd)

South san francisco, calif.--(business wire)--genentech, a member of the roche group (six: ro, rog; otcqx: rhhby), announced today new data from the avonelle-x and salween studies of vabysmo® (faricimab-svoa), presented at the 25th euretina congress in paris, france. data from the open-label avonelle-x study reinforce the efficacy, safety and durability of vabysmo over four years in wet age-related macular degeneration (amd), a leading cause of vision loss. in the single-arm salween study, vaby.
AMD Ratings Summary
AMD Quant Ranking